These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 18393375)
1. Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease. Naganuma M; Sakuraba A; Hisamatsu T; Ochiai H; Hasegawa H; Ogata H; Iwao Y; Hibi T Inflamm Bowel Dis; 2008 Sep; 14(9):1259-64. PubMed ID: 18393375 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of infliximab in patients with intestinal Behçet's disease refractory to conventional medication. Kinoshita H; Kunisaki R; Yamamoto H; Matsuda R; Sasaki T; Kimura H; Tanaka K; Naganuma M; Maeda S Intern Med; 2013; 52(17):1855-62. PubMed ID: 23994973 [TBL] [Abstract][Full Text] [Related]
3. Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody. Travis SP; Czajkowski M; McGovern DP; Watson RG; Bell AL Gut; 2001 Nov; 49(5):725-8. PubMed ID: 11600479 [TBL] [Abstract][Full Text] [Related]
4. A case of intestinal Behçet's disease treated with infliximab monotherapy who successfully maintained clinical remission and complete mucosal healing for six years. Maruyama Y; Hisamatsu T; Matsuoka K; Naganuma M; Inoue N; Ogata H; Iwao Y; Kanai T; Hibi T Intern Med; 2012; 51(16):2125-9. PubMed ID: 22892489 [TBL] [Abstract][Full Text] [Related]
5. Long-Term Outcomes and Predictors of Sustained Response in Patients with Intestinal Behcet's Disease Treated with Infliximab. Zou J; Ji DN; Cai JF; Guan JL; Bao ZJ Dig Dis Sci; 2017 Feb; 62(2):441-447. PubMed ID: 28044230 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet's disease. Iwata S; Saito K; Yamaoka K; Tsujimura S; Nawata M; Hanami K; Tanaka Y Mod Rheumatol; 2011 Apr; 21(2):184-91. PubMed ID: 21052764 [TBL] [Abstract][Full Text] [Related]
7. Remission of intestinal Behçet's disease treated with anti-tumor necrosis factor alpha monoclonal antibody (Infliximab). Lee JH; Kim TN; Choi ST; Jang BI; Shin KC; Lee SB; Shim YR Korean J Intern Med; 2007 Mar; 22(1):24-7. PubMed ID: 17427642 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of infliximab in intestinal Behçet's disease: a Korean multicenter retrospective study. Lee JH; Cheon JH; Jeon SW; Ye BD; Yang SK; Kim YH; Lee KM; Im JP; Kim JS; Lee CK; Kim HJ; Kim EY; Kim KO; Jang BI; Kim WH Inflamm Bowel Dis; 2013 Aug; 19(9):1833-8. PubMed ID: 23702810 [TBL] [Abstract][Full Text] [Related]
10. Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease. Park J; Cheon JH Gut Liver; 2018 Nov; 12(6):623-632. PubMed ID: 29788675 [TBL] [Abstract][Full Text] [Related]
11. Characteristics of patients with intestinal Behçet's disease requiring treatment with immunosuppressants or anti-TNFα antibody. Kimura Y; Asako K; Kikuchi H; Kono H Mod Rheumatol; 2016; 26(1):132-7. PubMed ID: 26025434 [TBL] [Abstract][Full Text] [Related]
12. Intestinal Behçet's disease appearing during treatment with adalimumab in a patient with ankylosing spondylitis. Chung SH; Park SJ; Hong SP; Cheon JH; Kim TI; Kim WH World J Gastroenterol; 2013 Aug; 19(32):5389-92. PubMed ID: 23983446 [TBL] [Abstract][Full Text] [Related]
13. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report. Hassard PV; Binder SW; Nelson V; Vasiliauskas EA Gastroenterology; 2001 Mar; 120(4):995-9. PubMed ID: 11231954 [TBL] [Abstract][Full Text] [Related]
14. Remission induction, maintenance, and endoscopic outcome with oral 5-aminosalicylic acid in intestinal Behçet's disease. Kinoshita H; Nishioka H; Ikeda A; Ikoma K; Sameshima Y; Ohi H; Tatsuno M; Kouyama J; Kawamoto C; Mitsui T; Tamura Y; Hashimoto Y; Nishio M; Ogashiwa T; Saigusa Y; Maeda S; Kimura H; Kunisaki R; Koike K J Gastroenterol Hepatol; 2019 Nov; 34(11):1929-1939. PubMed ID: 31017728 [TBL] [Abstract][Full Text] [Related]
15. Antitumor necrosis factor-alpha therapy for early postoperative recurrence of gastrointestinal Behçet's disease: report of a case. Byeon JS; Choi EK; Heo NY; Hong SC; Myung SJ; Yang SK; Kim JH; Song JK; Yoo B; Yu CS Dis Colon Rectum; 2007 May; 50(5):672-6. PubMed ID: 17216141 [TBL] [Abstract][Full Text] [Related]
16. The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet's disease: indication of anti-TNFα monoclonal antibodies. Hisamatsu T; Ueno F; Matsumoto T; Kobayashi K; Koganei K; Kunisaki R; Hirai F; Nagahori M; Matsushita M; Kobayashi K; Kishimoto M; Takeno M; Tanaka M; Inoue N; Hibi T J Gastroenterol; 2014 Jan; 49(1):156-62. PubMed ID: 23955155 [TBL] [Abstract][Full Text] [Related]
17. Improvement of neurological and ocular symptoms of Behçet's disease after the introduction of infliximab. Barešić M; Reihl M; Habek M; Vukojević N; Anić B Rheumatol Int; 2018 Jul; 38(7):1301-1306. PubMed ID: 29777341 [TBL] [Abstract][Full Text] [Related]
18. Predictors of infliximab refractory intestinal Behçet's syndrome: A retrospective cohort study from the Shanghai Behçet's syndrome database. Bao HF; Hou CC; Ye B; Zou J; Luo D; Cai JF; Shen Y; Guan JL Mod Rheumatol; 2023 Jan; 33(1):207-216. PubMed ID: 34932796 [TBL] [Abstract][Full Text] [Related]
20. Induction of ocular Behçet's disease remission after short-term treatment with infliximab: a case series of 11 patients with a follow-up from 4 to 16 years. Sfikakis PP; Arida A; Ladas DS; Markomichelakis N Clin Exp Rheumatol; 2019; 37 Suppl 121(6):137-141. PubMed ID: 31856941 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]